Home

Clay Thorp

CIK 1592380 · last filed 2025-02-24

Clay Thorp is a corporate insider who has filed 49 SEC Form 4 insider transactions across 3 companies since 2016. The most recent filing shows the insider bought $13.8K of CLSD on Feb 24, 2025. Across all open-market trades the lifetime net is +$23.3M, making them a net buyer over the disclosed history. 10 SEC filings were submitted jointly with John Crumpler.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$0

Companies

3

Total Filings

49

Lifetime Open-Market Net

$23.32M

Filer Profile

Reported Address
C/O HATTERAS VENTURE PARTNERS III, LP
280 S. MANGUM ST., SUITE 350
DURHAM, NC 27701
Related Filers
John Crumpler — 10 joint filings, latest 2018-06-01
ROBERT ALEXANDER INGRAM — 10 joint filings, latest 2018-06-01
KENNETH B LEE JR — 10 joint filings, latest 2018-06-01
Douglas MD Reed — 10 joint filings, latest 2018-06-01
Hatteras Venture Advisors IV SBIC, LLC — 7 joint filings, latest 2018-06-01
Hatteras Venture Advisors III, LLC — 3 joint filings, latest 2017-01-19
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
Clearside Biomedical, Inc. (CLSD) Delisted Director 248,079 $0.35 $87.2K $17.97M 33 2025-02-24
PhaseBio Pharmaceuticals Inc (PHAS) Delisted Director 48,375 $0.07 $3.4K $1.51M 12 2022-05-20
Vigil Neuroscience, Inc. (VIGL) Delisted Director 1,544,137 $8.05 $12.43M $3.84M 3 2022-05-17

Recent Filings

49 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2025-02-24 Clearside Biomedical, Inc. (CLSD) Delisted Buy (P) +15,000 $13.8K EDGAR
2024-06-21 Clearside Biomedical, Inc. (CLSD) Delisted Grant (A) — $0 EDGAR
2023-09-25 Clearside Biomedical, Inc. (CLSD) Delisted Buy (P) +10,000 $8.6K EDGAR
2023-06-23 Clearside Biomedical, Inc. (CLSD) Delisted Grant (A) — $0 EDGAR
2023-05-19 — Exer (M) +3,750 $0
2022-12-21 Clearside Biomedical, Inc. (CLSD) Delisted Buy (P) +14,000 $14.3K EDGAR
2022-12-19 Clearside Biomedical, Inc. (CLSD) Delisted Other (J) −1,397,985 $0 EDGAR
2022-12-19 Clearside Biomedical, Inc. (CLSD) Delisted Sell (S) −32,873 -$145.6K EDGAR
2022-06-24 Clearside Biomedical, Inc. (CLSD) Delisted Grant (A) — $0 EDGAR
2022-05-20 PhaseBio Pharmaceuticals Inc (PHAS) Delisted Grant (A) — $0 EDGAR
Showing 1–10 of 49
Page 1 of 5
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.